David A. Siegel Lipocine Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.3 - $0.58 $9,150 - $17,690	-30,500 Reduced 18.77%	132,000 $42,000
Q4 2022 Feb 14, 2023	SELL	$0.37 - $8.65 $17,427 - $407,415	-47,100 Reduced 22.47%	162,500 $65,000
Q3 2022 Nov 14, 2022	SELL	$0.49 - $7.65 $49,000 - $765,000	-100,000 Reduced 32.3%	209,600 $94,000
Q2 2022 Aug 15, 2022	BUY	$0.73 - $1.34 $122,056 - $224,048	167,200 Added 117.42%	309,600 $248,000
Q1 2022 May 16, 2022	BUY	$0.89 - $1.85 $79,566 - $165,390	89,400 Added 168.68%	142,400 $195,000
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.2 $52,470 - $63,600	53,000 New	53,000 $53,000
Q2 2021 Aug 16, 2021	SELL	$1.17 - $1.59 $30,302 - $41,181	-25,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.38 - $2.28 $35,742 - $59,051	25,900 New	25,900 $39,000
Q4 2020 Feb 16, 2021	SELL	$1.2 - $1.69 $18,120 - $25,519	-15,100 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.21 - $2.23 $4,114 - $7,582	-3,400 Reduced 18.38%	15,100 $21,000
Q2 2020 Aug 14, 2020	BUY	$0.42 - $1.26 $7,770 - $23,310	18,500 New	18,500 $23,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $418M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.